Mintz Life Sciences Deal Activity (April – June 2021)
Mergers & Acquisitions
- Represented Quantum-SI (NASDAQ: QSI), a pioneer in next generation semiconductor chip-based proteomics, in its business combination with the healthcare focused SPAC, HighCape Capital Acquisition Corporation (June 2021)
- Represented Myriad Genetics, Inc. (NASDAQ: MYGN), a genetic testing and precision medicine company, in multiple carveout transactions, including its sale of Myriad RBM, Inc., which specializes in contract research services for the pharmaceutical industry, to Q2 Solutions, a global clinical trial laboratory services organization, and a wholly owned subsidiary of IQVIA, and its sale of its myPath Melanoma screening test to Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions (June 2021)
- Represented Philips Healthcare in the sale of its Aging and Caregiving business to Connect America, a portfolio company of Rockbridge Growth Equity (June 2021)
- Representing Medly Pharmacy, a full-service, digital pharmacy that offers free same-day prescription delivery for all types of medications, in its proposed acquisition of Pharmaca, Inc., the nation’s first integrative pharmacy chain offering traditional pharmacy services alongside natural and complementary health solutions (June 2021)
- Representing Vicarious Surgical Inc., a next-generation surgical robotics company, in its proposed business combination with the SPAC, D8 Holdings Corp. (NYSE: DEH) (April 2021)
- Represented Brooks Automation in its acquisition of Precise Automation, Inc., a leading developer of collaborative robots and automation subsytems (April 2021)
Venture Capital
- Represented PFM Health Sciences in a crossover financing of Turnstone Biologics, a company working on viral immunotherapies for cancer (June 2021)
- Represented NFP Venture LLC in a Series C financing of Kindbody, an operator of fertility and women's health clinics (May 2021)
- Represented LifeForce Capital Fund II in a Series A financing of Positive Development Inc., a care and therapy platform for children with autism and other developmental differences (April 2021)
- Represented CAM Capital as co-lead investor in a $115M Series C financing for Arcellx, Inc., a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases (April 2021)
- Represented New Equilibrium Biosciences, Inc. in its $10M Seed-stage financing (April 2021)
Capital Markets
Represented the issuer:
- Represented Acurx Pharmaceuticals, Inc. in its $15M initial public offering underwritten by Alexander Capital, L.P. and Network 1 Financial Securities Inc. (June 2021)
- Represented SELLAS Life Sciences in its $50M at-the-market offering with Cantor Fitzgerald acting as sales agent (June 2021)
- Represented Evofem Biosciences, Inc. in its $50M public offering underwritten by H.C. Wainwright & Co., LLC (May 2021)
- Represented F-star Therapeutics, Inc. in its $65M public offering underwritten by H.C. Wainwright & Co., LLC, Oppenheimer & Co. Inc. and SVB Leerink LLC (May 2021)
- Represented Synlogic, Inc. in its $30M public offering underwritten by SVB Leerink LLC (April 2021)
Represented the underwriters:
- Represented the underwriters in the $40M public offering of Novan, Inc. underwritten by Cantor Fitzgerald (June 2021)
- Represented the underwriters in the $45M public offering of PDS Biotechnology Corporation underwritten by Cantor Fitzgerald (June 2021)
- Represented the underwriters in the $60M public offering of Seelos Therapeutics, Inc. underwritten by Cantor Fitzgerald & Co., BTIG, LLC and Guggenheim Securities, LLC (June 2021)
- Represented the underwriters in the $91.25M public offering of Praxis Precision Medicines, Inc. underwritten by BofA Securities, Inc., Wedbush Securities Inc., Piper Sandler & Co. and Cowen Securities LLC (May 2021)
- Represented the underwriters in the $25M public offering of Vascular Biogenics Ltd. underwritten by Roth Capital Partners, LLC, Oppenheimer & Co. Inc., JonesTrading Institutional Services, LLC and Guggenheim Securities, LLC (April 2021)
View Deal Activity from April – June 2020
View Deal Activity from July – September 2020
View Deal Activity from October – December 2020